A pill helping boost women's sex drive, described by some as the ‘female Viagra’ failed as it underwent a unanimous vote by the advisory panel for the US Food and Drug Administration, where is was disapproved.

Flibanserin, is made by the German Company, Boehringer Ingelhein and the FDA's Reproductive Health Drugs Advisory Committee said the evidence presented did not demonstrate the effectiveness or the safety of the pill.

Julia Johnson, Chief of obstetrics and gynecology at the University Of Massachusetts Medical School said “The efficacy was not sufficiently robust to justify the risks”.

Even though, the FDA is not required to follow the panel’s advice but it still continues to do it.

Flibanserin, the hottest attempt to come up with a female complement to the passionately accepted male erectile dysfunction pill Viagra, works on the brain chemicals to take care of pre-menopausal women with a low sex drive, as per the maker.

In contrast to treatments for male sexual dysfunction, the drug known by the commercial name Girosa, has not been permitted for sale in any country.

Since Viagra instigated in 1998, becoming a huge sensation, and was consequently followed by competitors Cialis and Levitra, pharmaceutical firms have competed for a spot in this potential market, estimated to be worth two billion dollars.

Flibanserin belongs to a kin’s of anti-depressants that diminish the level of serotonin, which has an effect on mood and can put a constraint on sexual desire.

The drug also reins the levels of dopamine and norepinephrine in the blood, substances that act on sexual desire, the pill's manufacturer said.